1h Free Analyst Time
Speak directly to the analyst to clarify any post sales queries you may have.
1 of 4
FEATURED COMPANIES
- Allergan Plc
- Novartis AG
- Pfizer Inc.
- MORE
Global Open-Angle Glaucoma Therapeutics Market: About this market
Open-angle glaucoma is a condition of the eye that leads to progressive atrophy of the optic nerve in the presence of an open angle. This open-angle glaucoma therapeutics market analysis considers sales from both prostaglandin analogs (PGAs) and non-prostaglandin analogs (NPAs). Our analysis also considers the sales of open-angle glaucoma therapeutics in Asia, Europe, North America, and ROW. In 2018, the PGAs segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as first-line treatment option and increasing use of a combination of PGAs with other drugs will play a significant role in the PGAs segment to maintain its market position. Also, our global open-angle glaucoma therapeutics market report looks at factors such as promising pipeline and recent approvals and increasing demand for combination drugs. However, uncertainties in the advances in glaucoma surgery, low patient adherence of topical medications, and asymptomatic nature of open-angle glaucoma may hamper the growth of the glaucoma therapeutics industry over the forecast period.
Global Open-Angle Glaucoma Therapeutics Market: Overview
Increasing demand for combination drugs
Combination drugs aim at different targets or pathways to combat the disease with minimal adverse effects. Moreover, they also improve tolerability, as two compounds can be employed below their individual dose thresholds. The demand for combination drugs will increase owing to their advantages, which will subsequently lead the market to grow at a CAGR of over 4% during the forecast period.
Strategic alliances
The high prevalence of open-angle glaucoma and requirement of novel medication led pharmaceutical companies to focus on the development of new drugs to treat open-angle glaucoma. During the development of new drugs, numerous companies are forming collaborations with other companies, which will speed up the development process and also increase the investments in research. This development is expected to have a positive impact on the overall market growth.
Competitive Landscape
With the presence of several major players, the global open-angle glaucoma therapeutics market is fragmented. This robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading open-angle glaucoma therapeutics companies, that include Aerie Pharmaceuticals Inc., Allergan Plc, Bausch Health Companies Inc., Novartis AG, and Pfizer Inc.
Also, the open-angle glaucoma therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.
Open-angle glaucoma is a condition of the eye that leads to progressive atrophy of the optic nerve in the presence of an open angle. This open-angle glaucoma therapeutics market analysis considers sales from both prostaglandin analogs (PGAs) and non-prostaglandin analogs (NPAs). Our analysis also considers the sales of open-angle glaucoma therapeutics in Asia, Europe, North America, and ROW. In 2018, the PGAs segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as first-line treatment option and increasing use of a combination of PGAs with other drugs will play a significant role in the PGAs segment to maintain its market position. Also, our global open-angle glaucoma therapeutics market report looks at factors such as promising pipeline and recent approvals and increasing demand for combination drugs. However, uncertainties in the advances in glaucoma surgery, low patient adherence of topical medications, and asymptomatic nature of open-angle glaucoma may hamper the growth of the glaucoma therapeutics industry over the forecast period.
Global Open-Angle Glaucoma Therapeutics Market: Overview
Increasing demand for combination drugs
Combination drugs aim at different targets or pathways to combat the disease with minimal adverse effects. Moreover, they also improve tolerability, as two compounds can be employed below their individual dose thresholds. The demand for combination drugs will increase owing to their advantages, which will subsequently lead the market to grow at a CAGR of over 4% during the forecast period.
Strategic alliances
The high prevalence of open-angle glaucoma and requirement of novel medication led pharmaceutical companies to focus on the development of new drugs to treat open-angle glaucoma. During the development of new drugs, numerous companies are forming collaborations with other companies, which will speed up the development process and also increase the investments in research. This development is expected to have a positive impact on the overall market growth.
Competitive Landscape
With the presence of several major players, the global open-angle glaucoma therapeutics market is fragmented. This robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading open-angle glaucoma therapeutics companies, that include Aerie Pharmaceuticals Inc., Allergan Plc, Bausch Health Companies Inc., Novartis AG, and Pfizer Inc.
Also, the open-angle glaucoma therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.
Note: Product cover images may vary from those shown
2 of 4
FEATURED COMPANIES
- Allergan Plc
- Novartis AG
- Pfizer Inc.
- MORE
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 08: GEOGRAPHIC LANDSCAPE
PART 10: DRIVERS AND CHALLENGES
PART 12: VENDOR LANDSCAPE
Exhibit 01: Global pharmaceuticals market
Exhibit 02: Segments of global pharmaceuticals market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition - Inclusions and exclusions checklist
Exhibit 06: Market size 2018
Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 09: Five forces analysis 2018
Exhibit 10: Five forces analysis 2023
Exhibit 11: Bargaining power of buyers
Exhibit 12: Bargaining power of suppliers
Exhibit 13: Threat of new entrants
Exhibit 14: Threat of substitutes
Exhibit 15: Threat of rivalry
Exhibit 16: Market condition - Five forces 2018
Exhibit 17: Product - Market share 2018-2023 (%)
Exhibit 18: Comparison by product
Exhibit 19: PGAs - Market size and forecast 2018-2023 ($ millions)
Exhibit 20: PGAs - Year-over-year growth 2019-2023 (%)
Exhibit 21: Non-PGAs - Market size and forecast 2018-2023 ($ millions)
Exhibit 22: Non-PGAs - Year-over-year growth 2019-2023 (%)
Exhibit 23: Market opportunity by product
Exhibit 24: Customer landscape
Exhibit 25: Market share by geography 2018-2023 (%)
Exhibit 26: Geographic comparison
Exhibit 27: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 28: Projections for glaucoma (2010, 2030, and 2050)
Exhibit 29: North America - Year-over-year growth 2019-2023 (%)
Exhibit 30: Top 3 countries in North America
Exhibit 31: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 32: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 33: Top 3 countries in Europe
Exhibit 34: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 35: Population aged 65 years and above (% of total) in Asia 2017
Exhibit 36: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 37: Top 3 countries in Asia
Exhibit 38: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 39: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 40: Top 3 countries in ROW
Exhibit 41: Key leading countries
Exhibit 42: Market opportunity
Exhibit 43: Some late-stage drugs in pipeline for open-angle glaucoma treatment
Exhibit 44: Some of the combination drugs
Exhibit 45: Impact of drivers and challenges
Exhibit 46: Vendor landscape
Exhibit 47: Landscape disruption
Exhibit 48: Vendors covered
Exhibit 49: Vendor classification
Exhibit 50: Market positioning of vendors
Exhibit 51: Aerie Pharmaceuticals Inc. - Vendor overview
Exhibit 52: Aerie Pharmaceuticals Inc. - Business segments
Exhibit 53: Aerie Pharmaceuticals Inc. - Organizational developments
Exhibit 54: Aerie Pharmaceuticals Inc. - Key offerings
Exhibit 55: Aerie Pharmaceuticals Inc. - Key customers
Exhibit 56: Allergan Plc - Vendor overview
Exhibit 57: Allergan Plc - Business segments
Exhibit 58: Allergan Plc - Organizational developments
Exhibit 59: Allergan Plc - Geographic focus
Exhibit 60: Allergan Plc - Segment focus
Exhibit 61: Allergan Plc - Key offerings
Exhibit 62: Allergan Plc - Key customers
Exhibit 63: Bausch Health Companies Inc. - Vendor overview
Exhibit 64: Bausch Health Companies Inc. - Product segments
Exhibit 65: Bausch Health Companies Inc. - Organizational developments
Exhibit 66: Bausch Health Companies Inc. - Geographic focus
Exhibit 67: Bausch Health Companies Inc. - Segment focus
Exhibit 68: Bausch Health Companies Inc. - Key offerings
Exhibit 69: Bausch Health Companies Inc. - Key customers
Exhibit 70: Novartis AG - Vendor overview
Exhibit 71: Novartis AG - Business segments
Exhibit 72: Novartis AG - Organizational developments
Exhibit 73: Novartis AG - Geographic focus
Exhibit 74: Novartis AG - Segment focus
Exhibit 75: Novartis AG - Key offerings
Exhibit 76: Novartis AG - Key customers
Exhibit 77: Pfizer Inc. - Vendor overview
Exhibit 78: Pfizer Inc. - Business segments
Exhibit 79: Pfizer Inc. - Organizational developments
Exhibit 80: Pfizer Inc. - Geographic focus
Exhibit 81: Pfizer Inc. - Segment focus
Exhibit 82: Pfizer Inc. - Key offerings
Exhibit 83: Pfizer Inc. - Key customers
Exhibit 84: Validation techniques employed for market sizing
Exhibit 85: Definition of market positioning of vendors
PART 02: SCOPE OF THE REPORT
- Preface
- Currency conversion rates for US$
- Market ecosystem
- Market characteristics
- Market segmentation analysis
- Market definition
- Market sizing 2018
- Market size and forecast 2018-2023
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition
- Market segmentation by product
- Comparison by product
- PGAs - Market size and forecast 2018-2023
- Non-PGAs - Market size and forecast 2018-2023
- Market opportunity by product
PART 08: GEOGRAPHIC LANDSCAPE
- Geographic segmentation
- Geographic comparison
- North America - Market size and forecast 2018-2023
- Europe - Market size and forecast 2018-2023
- Asia - Market size and forecast 2018-2023
- ROW - Market size and forecast 2018-2023
- Key leading countries
- Market opportunity
PART 10: DRIVERS AND CHALLENGES
- Market drivers
- Market challenges
PART 12: VENDOR LANDSCAPE
- Overview
- Landscape disruption
- Competitive scenario
- Vendors covered
- Vendor classification
- Market positioning of vendors
- Aerie Pharmaceuticals Inc.
- Allergan Plc
- Bausch Health Companies Inc.
- Novartis AG
- Pfizer Inc.
- Research methodology
- List of abbreviations
- Definition of market positioning of vendors
Exhibit 01: Global pharmaceuticals market
Exhibit 02: Segments of global pharmaceuticals market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition - Inclusions and exclusions checklist
Exhibit 06: Market size 2018
Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 09: Five forces analysis 2018
Exhibit 10: Five forces analysis 2023
Exhibit 11: Bargaining power of buyers
Exhibit 12: Bargaining power of suppliers
Exhibit 13: Threat of new entrants
Exhibit 14: Threat of substitutes
Exhibit 15: Threat of rivalry
Exhibit 16: Market condition - Five forces 2018
Exhibit 17: Product - Market share 2018-2023 (%)
Exhibit 18: Comparison by product
Exhibit 19: PGAs - Market size and forecast 2018-2023 ($ millions)
Exhibit 20: PGAs - Year-over-year growth 2019-2023 (%)
Exhibit 21: Non-PGAs - Market size and forecast 2018-2023 ($ millions)
Exhibit 22: Non-PGAs - Year-over-year growth 2019-2023 (%)
Exhibit 23: Market opportunity by product
Exhibit 24: Customer landscape
Exhibit 25: Market share by geography 2018-2023 (%)
Exhibit 26: Geographic comparison
Exhibit 27: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 28: Projections for glaucoma (2010, 2030, and 2050)
Exhibit 29: North America - Year-over-year growth 2019-2023 (%)
Exhibit 30: Top 3 countries in North America
Exhibit 31: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 32: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 33: Top 3 countries in Europe
Exhibit 34: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 35: Population aged 65 years and above (% of total) in Asia 2017
Exhibit 36: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 37: Top 3 countries in Asia
Exhibit 38: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 39: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 40: Top 3 countries in ROW
Exhibit 41: Key leading countries
Exhibit 42: Market opportunity
Exhibit 43: Some late-stage drugs in pipeline for open-angle glaucoma treatment
Exhibit 44: Some of the combination drugs
Exhibit 45: Impact of drivers and challenges
Exhibit 46: Vendor landscape
Exhibit 47: Landscape disruption
Exhibit 48: Vendors covered
Exhibit 49: Vendor classification
Exhibit 50: Market positioning of vendors
Exhibit 51: Aerie Pharmaceuticals Inc. - Vendor overview
Exhibit 52: Aerie Pharmaceuticals Inc. - Business segments
Exhibit 53: Aerie Pharmaceuticals Inc. - Organizational developments
Exhibit 54: Aerie Pharmaceuticals Inc. - Key offerings
Exhibit 55: Aerie Pharmaceuticals Inc. - Key customers
Exhibit 56: Allergan Plc - Vendor overview
Exhibit 57: Allergan Plc - Business segments
Exhibit 58: Allergan Plc - Organizational developments
Exhibit 59: Allergan Plc - Geographic focus
Exhibit 60: Allergan Plc - Segment focus
Exhibit 61: Allergan Plc - Key offerings
Exhibit 62: Allergan Plc - Key customers
Exhibit 63: Bausch Health Companies Inc. - Vendor overview
Exhibit 64: Bausch Health Companies Inc. - Product segments
Exhibit 65: Bausch Health Companies Inc. - Organizational developments
Exhibit 66: Bausch Health Companies Inc. - Geographic focus
Exhibit 67: Bausch Health Companies Inc. - Segment focus
Exhibit 68: Bausch Health Companies Inc. - Key offerings
Exhibit 69: Bausch Health Companies Inc. - Key customers
Exhibit 70: Novartis AG - Vendor overview
Exhibit 71: Novartis AG - Business segments
Exhibit 72: Novartis AG - Organizational developments
Exhibit 73: Novartis AG - Geographic focus
Exhibit 74: Novartis AG - Segment focus
Exhibit 75: Novartis AG - Key offerings
Exhibit 76: Novartis AG - Key customers
Exhibit 77: Pfizer Inc. - Vendor overview
Exhibit 78: Pfizer Inc. - Business segments
Exhibit 79: Pfizer Inc. - Organizational developments
Exhibit 80: Pfizer Inc. - Geographic focus
Exhibit 81: Pfizer Inc. - Segment focus
Exhibit 82: Pfizer Inc. - Key offerings
Exhibit 83: Pfizer Inc. - Key customers
Exhibit 84: Validation techniques employed for market sizing
Exhibit 85: Definition of market positioning of vendors
Note: Product cover images may vary from those shown
3 of 4
LOADING...
4 of 4
FEATURED COMPANIES
- Allergan Plc
- Novartis AG
- Pfizer Inc.
- MORE
The following companies are recognised as the key players in the global open-angle glaucoma therapeutics market: Aerie Pharmaceuticals Inc., Allergan Plc, Bausch Health Companies Inc., Novartis AG, and Pfizer Inc.
Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the development of the strategic alliances”
According to the report, one of the major drivers for this market is the Increasing demand for combination drugs.
Further, the report states that one of the major factors hindering the growth of this market is the advances in glaucoma surgery.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the development of the strategic alliances”
According to the report, one of the major drivers for this market is the Increasing demand for combination drugs.
Further, the report states that one of the major factors hindering the growth of this market is the advances in glaucoma surgery.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 4
- Aerie Pharmaceuticals Inc.
- Allergan Plc
- Bausch Health Companies Inc.
- Novartis AG
- Pfizer Inc.
Note: Product cover images may vary from those shown
